Synthesis, characterization, DNA binding interactions, DFT calculations, and Covid-19 molecular docking of novel bioactive copper(I) complexes developed via unexpected reduction of azo-hydrazo ligands.

In this work, we focused on the 3rd goal of the sustainable development plan: achieving good health and supporting well-being. Two redox-active hydrazo ligands namely, phenylcarbonohydrazonoyldicyanide (PCHD) and pyridin-4-ylcarbonohydrazonoyl-dicyanide (PyCHD), and their copper(I) complexes have been synthesized and characterized. The analytical data indicates the formation of copper(I) complexes despite starting with copper(II) perchlorate salt.

Synthesis of a Novel Unexpected Cu(II)-Thiazolidine Complex-X-ray Structure, Hirshfeld Surface Analysis, and Biological Studies.

An unexpected trinuclear Cu(II)-thiazolidine complex has been synthesized by mixing CuCl·2HO with the Schiff base ligand, 1-(((4,5-dihydrothiazol-2-yl)ethylidene)hydrazono)methyl)phenol , in ethanol. Unexpectedly, the reaction proceeded via the hydrolysis of the Schiff base , followed by cyclization to afford 3-methyl-5,6-dihydrothiazolo[3,2-][1,2,3]triazole (), then complexation with the Cu(II) salt, forming the trinuclear complex. The complex was characterized by means of FTIR spectra, elemental analysis, and X-ray crystallography.